A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

NCT00782093 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
63
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Ophthotech Corporation